INO 2002

Drug Profile

INO 2002

Alternative Names: IMS; Inosine analogue - Inotek; Inosinergic agonist - Inotek

Latest Information Update: 13 Sep 2007

Price : $50

At a glance

  • Originator Inotek Pharmaceuticals
  • Class Nucleosides
  • Mechanism of Action Chemokine receptor antagonists; Cytokine inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 13 Sep 2007 Discontinued - Phase-I for Ulcerative colitis in USA (PO)
  • 13 Sep 2007 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
  • 24 Feb 2006 Phase-I clinical trials in Ulcerative colitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top